TY - JOUR
T1 - The Economic Impact of Optimizing a COVID-19 Management Protocol in Pre-Existing Cardiovascular Disease Patients
AU - Abushanab, Dina
AU - Eldebs, Mohammed
AU - Basha, Ahmed
AU - Naseralallah, Lina
AU - Kazkaz, Hadia
AU - Moursi, Ahmed
AU - Albazoon, Fatima
AU - Wafi, Omar
AU - Badran, Saif
AU - Doi, Suhail A.R.
AU - Al-Maadeed, Somaya
AU - Alam, Mohammed Fasihul
AU - Al-Badriyeh, Daoud
N1 - Publisher Copyright:
© 2022 The Authors
PY - 2023/8
Y1 - 2023/8
N2 - This study answers the question of whether the health care costs of managing COVID-19 in preexisting cardiovascular diseases (CVD) patients increased or decreased as a consequence of evidence-based efforts to optimize the initial COVID-19 management protocol in a CVD group of patients. A retrospective cohort study was conducted in preexisting CVD patients with COVID-19 in Hamad Medical Corporation, Qatar. From the health care perspective, only direct medical costs were considered, adjusted to their 2021 values. The impact of revising the protocol was a reduction in the overall costs in non-critically ill patients from QAR15,447 (USD 4243) to QAR4337 (USD 1191) per patient, with an economic benefit of QAR11,110 (USD 3051). In the critically ill patients, however, the cost increased from QAR202,094 (USD 55,505) to QAR292,856 (USD 80,433) per patient, with added cost of QAR90,762 (USD 24,928). Overall, regardless of critical care status, the optimization of the initial COVID-19 protocols in patients with preexisting CVD did not reduce overall health care costs, but increased it by QAR80,529 (USD 22,117) per patient.
AB - This study answers the question of whether the health care costs of managing COVID-19 in preexisting cardiovascular diseases (CVD) patients increased or decreased as a consequence of evidence-based efforts to optimize the initial COVID-19 management protocol in a CVD group of patients. A retrospective cohort study was conducted in preexisting CVD patients with COVID-19 in Hamad Medical Corporation, Qatar. From the health care perspective, only direct medical costs were considered, adjusted to their 2021 values. The impact of revising the protocol was a reduction in the overall costs in non-critically ill patients from QAR15,447 (USD 4243) to QAR4337 (USD 1191) per patient, with an economic benefit of QAR11,110 (USD 3051). In the critically ill patients, however, the cost increased from QAR202,094 (USD 55,505) to QAR292,856 (USD 80,433) per patient, with added cost of QAR90,762 (USD 24,928). Overall, regardless of critical care status, the optimization of the initial COVID-19 protocols in patients with preexisting CVD did not reduce overall health care costs, but increased it by QAR80,529 (USD 22,117) per patient.
UR - https://www.scopus.com/pages/publications/85130341579
U2 - 10.1016/j.cpcardiol.2022.101177
DO - 10.1016/j.cpcardiol.2022.101177
M3 - Article
C2 - 35341802
AN - SCOPUS:85130341579
SN - 0146-2806
VL - 48
JO - Current problems in cardiology
JF - Current problems in cardiology
IS - 8
M1 - 101177
ER -